GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » Debt-to-Revenue

Gongwin Biopharm Holdings Co (ROCO:6617) Debt-to-Revenue : 3.55 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Gongwin Biopharm Holdings Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Gongwin Biopharm Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$113.84 Mil. Gongwin Biopharm Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$12.91 Mil. Gongwin Biopharm Holdings Co's annualized Revenue for the quarter that ended in Dec. 2024 was NT$35.70 Mil. Gongwin Biopharm Holdings Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 3.55.


Gongwin Biopharm Holdings Co Debt-to-Revenue Historical Data

The historical data trend for Gongwin Biopharm Holdings Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gongwin Biopharm Holdings Co Debt-to-Revenue Chart

Gongwin Biopharm Holdings Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.32 100.74 124.01 4.08 3.96

Gongwin Biopharm Holdings Co Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 3.87 7.11 3.19 3.55

Competitive Comparison of Gongwin Biopharm Holdings Co's Debt-to-Revenue

For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gongwin Biopharm Holdings Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gongwin Biopharm Holdings Co's Debt-to-Revenue falls into.


;
;

Gongwin Biopharm Holdings Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Gongwin Biopharm Holdings Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(113.842 + 12.906) / 32.04
=3.96

Gongwin Biopharm Holdings Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(113.842 + 12.906) / 35.696
=3.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Gongwin Biopharm Holdings Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gongwin Biopharm Holdings Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gongwin Biopharm Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.

Gongwin Biopharm Holdings Co Headlines

No Headlines